China Health Group Inc. (8225) AI Stock Analysis

• Market Cap: €170.21M
• Dividend Yield: N/A
• Average Volume (3M): 143.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 19.97%
• EPS Growth: 76.51%
• Country: HK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Diagnostics & Research
• EPS (TTM): <0.01
• Shares Outstanding: 995,351,700
• 10 Day Avg. Volume: 190,000
• 30 Day Avg. Volume: 143,666
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

China Health Group Inc. has a low overall stock score, primarily due to significant challenges in financial performance, including declining revenues and profitability. Technical analysis further supports a bearish outlook with negative momentum indicators. Valuation metrics are unattractive due to a negative P/E ratio and lack of dividend yield, making the stock less appealing. The absence of earnings call data and corporate events limits additional insights.

China Health Group Inc. Business Overview & Revenue Model

Company Description

China Health Group Inc. (8225) is a healthcare-focused company operating primarily in China. It is engaged in various sectors within the healthcare industry, including the provision of medical services, healthcare management, and the development and distribution of healthcare products. The company aims to improve healthcare delivery and accessibility by leveraging its expertise and resources across these sectors.

How the Company Makes Money

China Health Group Inc. generates revenue through several key streams. The company earns income from providing medical services, which may include hospital operations, outpatient services, and specialty care. Additionally, it manages healthcare facilities, offering operational and administrative expertise to improve efficiency and patient care. Another significant revenue stream is the development and distribution of healthcare products, which can include pharmaceuticals, medical devices, and health supplements. Partnerships with other healthcare organizations and governmental bodies may also contribute to its revenue, as they can enhance service delivery and expand market reach. These various activities collectively support the company's earnings and growth strategy.

China Health Group Inc. Financial Statement Overview

Summary

China Health Group Inc. faces challenges with declining revenues and profitability, impacting its income statement negatively. The balance sheet shows a strong equity position with no debt, but with decreasing total assets. Cash flow management remains a concern with fluctuating and often negative cash flows. The company needs to address its revenue and profitability issues while maintaining its solid equity structure to improve financial health.

Income Statement

China Health Group Inc. has experienced a significant decline in revenue from 2021 to 2024, with a consistent negative trend in net income and EBIT margins. The gross profit margin has remained relatively stable, but the net profit margin is negative, indicating ongoing profitability challenges. The company had a steep revenue drop from 2021 to 2022, which has not fully recovered.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio of 0, indicating no reliance on debt financing. However, stockholders' equity has decreased over the years, reflecting potential risks in asset management. The equity ratio is strong, suggesting a stable financial structure despite declining total assets.

Cash Flow

Cash flow from operating activities has been volatile, with a notable improvement in free cash flow from 2023 to 2024. However, the company has been unable to generate consistent positive cash flows, and free cash flow remains negative. The cash flow to net income ratios are not available due to negative net income, indicating cash flow management issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.45M	21.43M	13.09M	83.60M	83.06M
Gross Profit	10.07M	8.21M	5.74M	63.86M	66.96M
EBITDA	-14.24M	-57.98M	-15.66M	42.74M	55.66M
Net Income	-14.52M	-58.01M	-15.84M	36.33M	60.65M
Balance Sheet
Total Assets	100.96M	119.35M	178.63M	198.11M	159.90M
Cash, Cash Equivalents and Short-Term Investments	15.89M	7.30M	12.07M	17.02M	28.35M
Total Debt	0.00	0.00	0.00	0.00	1.50M
Total Liabilities	31.24M	35.17M	36.74M	42.54M	41.22M
Stockholders Equity	70.35M	84.82M	142.32M	155.57M	118.67M
Cash Flow
Free Cash Flow	8.52M	-4.88M	-5.16M	-10.28M	19.11M
Operating Cash Flow	10.28M	1.12M	-5.16M	-10.28M	19.11M
Investing Cash Flow	-230.00K	-1.04M	-2.15M	6.96M	-11.97M
Financing Cash Flow	0.00	0.00	0.00	-1.51M	593.00K

China Health Group Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8225, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.17, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.66 is Neutral, neither overbought nor oversold. The STOCH value of 25.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8225.

China Health Group Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$225.38M	9.43	10.72%	4.46%	-22.12%	-28.95%
0928	58 Neutral	HK$173.94M	12.21	4.95%	―	-25.28%	―
2159	54 Neutral	HK$420.00M	―	-35.99%	―	-5.38%	63.93%
Sector *	51 Neutral	$7.95B	-0.38	-42.44%	2.22%	22.30%	-1.83%
8225	39 Underperform	€170.21M	―	-16.17%	―	19.97%	76.51%
1947	―	HK$216.06M	―	-20.93%	―	―	―
8622	48 Neutral	HK$197.69M	―	-8.71%	―	2.54%	33.33%